3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
13
Advanced Breast Cancer
2
Sarcoma, Endometrial Stromal
1
Recurrence
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Endometrial Neoplasms
1
ER+ Breast Cancer
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms, Male
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Adenosarcoma of the uterus
1
Interventions
Radiosurgery
23
Temozolomide
14
Magnetic Resonance Spectroscopy
14
pembrolizumab
11
Bevacizumab
11
Nivolumab
10
Ipilimumab
8
Memantine
7
Specimen Handling
6
abemaciclib
5
Radiotherapy
5
Mental Status and Dementia Tests
5
Blood Specimen Collection
5
Radiation
4
entrectinib
3
Surveys and Questionnaires
3
Sodium Chloride
3
Saline Solution
3
Receptors, Interleukin-8B
3
Proton Therapy
3
Lomustine
3
trastuzumab deruxtecan
2
trametinib
2
pertuzumab
2
osimertinib
2
lenvatinib
2
fluciclovine F-18
2
contrast agent BR1
2
atezolizumab
2
Watchful Waiting
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
elacestrant
×
90 days
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled